相似文献
1
Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.
Cancer Cell. 2007 Jan;11(1):6-8. doi: 10.1016/j.ccr.2006.12.008.
2
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021.
3
Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Cancer Res. 2012 Jan 15;72(2):402-7. doi: 10.1158/0008-5472.CAN-11-2464. Epub 2011 Nov 29.
4
Antiangiogenic therapy for glioblastoma.
Cancer J. 2012 Jan-Feb;18(1):45-50. doi: 10.1097/PPO.0b013e3182431c6f.
5
Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study.
Neoplasia. 2004 Sep-Oct;6(5):480-9. doi: 10.1593/neo.03520.
6
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.
Cancer Res. 2009 Jul 1;69(13):5296-300. doi: 10.1158/0008-5472.CAN-09-0814. Epub 2009 Jun 23.
7
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Mol Cancer Ther. 2008 Jan;7(1):71-8. doi: 10.1158/1535-7163.MCT-07-0552. Epub 2008 Jan 9.
8
Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
Pediatr Blood Cancer. 2008 Mar;50(3):581-7. doi: 10.1002/pbc.21232.
9
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
J Clin Oncol. 2010 Jun 10;28(17):2817-23. doi: 10.1200/JCO.2009.26.3988. Epub 2010 May 10.
10
Antiangiogenic therapy for glioblastoma: the challenge of translating response rate into efficacy.
Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e71.
引用本文的文献
1
Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature.
Cancer Cell Int. 2021 Mar 8;21(1):158. doi: 10.1186/s12935-021-01836-9.
2
New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment.
Front Oncol. 2019 Aug 28;9:840. doi: 10.3389/fonc.2019.00840. eCollection 2019.
3
Stem cell-based therapies for tumors in the brain: are we there yet?
Neuro Oncol. 2016 Aug;18(8):1066-78. doi: 10.1093/neuonc/now096. Epub 2016 Jun 9.
4
Avastin® in combination with gemcitabine and cisplatin significantly inhibits tumor angiogenesis and increases the survival rate of human A549 tumor-bearing mice.
Exp Ther Med. 2015 Jun;9(6):2180-2184. doi: 10.3892/etm.2015.2402. Epub 2015 Apr 1.
5
Reproducibility of magnetic resonance perfusion imaging.
PLoS One. 2014 Feb 25;9(2):e89797. doi: 10.1371/journal.pone.0089797. eCollection 2014.
6
Evidence for post-translational processing of vascular endothelial (VE)-cadherin in brain tumors: towards a candidate biomarker.
PLoS One. 2013 Dec 16;8(12):e80056. doi: 10.1371/journal.pone.0080056. eCollection 2013.
7
Cancer cell glycocalyx mediates mechanotransduction and flow-regulated invasion.
Integr Biol (Camb). 2013 Nov;5(11):1334-43. doi: 10.1039/c3ib40057c. Epub 2013 Sep 30.
8
Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth.
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13932-7. doi: 10.1073/pnas.1309629110. Epub 2013 Aug 5.
9
Progress in tumor vascular normalization for anticancer therapy: challenges and perspectives.
Front Med. 2012 Mar;6(1):67-78. doi: 10.1007/s11684-012-0176-8. Epub 2012 Mar 31.
10
Monitoring radiographic brain tumor progression.
Toxins (Basel). 2011 Mar;3(3):191-200. doi: 10.3390/toxins3030191. Epub 2011 Mar 15.
本文引用的文献
1
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021.
2
Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes.
Nat Med. 2006 May;12(5):557-67. doi: 10.1038/nm1400. Epub 2006 Apr 30.
3
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.
Neurology. 2006 Apr 25;66(8):1258-60. doi: 10.1212/01.wnl.0000208958.29600.87.
4
A physiologic imaging pilot study of breast cancer treated with AZD2171.
Clin Cancer Res. 2006 Jan 1;12(1):281-8. doi: 10.1158/1078-0432.CCR-05-0219.
5
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
N Engl J Med. 2005 Nov 10;353(19):2012-24. doi: 10.1056/NEJMoa051918.
6
AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.
Cancer Res. 2005 May 15;65(10):4389-400. doi: 10.1158/0008-5472.CAN-04-4409.
7
MGMT gene silencing and benefit from temozolomide in glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):997-1003. doi: 10.1056/NEJMoa043331.
8
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy.
Science. 2005 Jan 7;307(5706):58-62. doi: 10.1126/science.1104819.
9
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
Cancer Cell. 2004 Dec;6(6):553-63. doi: 10.1016/j.ccr.2004.10.011.
10
Perfusion MR imaging: basic principles and clinical applications.
Magn Reson Imaging Clin N Am. 2003 Aug;11(3):403-13. doi: 10.1016/s1064-9689(03)00066-7.
Zotero 插件